Posters

      Assessment of Mitochondrial Function Following Long-Term Treatment of Human Bronchial Epithelial Cells with Total Particulate Matter from a candidate Modified-Risk Tobacco Product versus Cigarettes

      Van der Toorn, M.; Malińska, D.; Szymanski, J.; Walczak, J.; Prill, M.; Drabik, K.; Michalska, B.; Wojtala, A.; Patalas-Krawczyk, P.; Partyka, M.; Johne, S. Johne.; Sewer, A.; Guedj, E.; Luettich, K.; Peitsch, M. C.; Hoeng, J.; Wieckowski, M.; Szczepanowska, J.; Duszynski, J.

      Conference date
      Aug 24, 2017
      Conference name

      Tenth World Congress - Alternatives and Animal Use in the Life Sciences
      Link to more information
      Topic
      Summary

      No abstract available.

      Related Publications

      Systems Toxicology Assessment of Aerosol from a Candidate Modified Risk Tobacco Product Compared with Cigarette Smoke on Organotypic Gingival Epithelial Cultures

      Aerosol Chemistry Systems Toxicology

      Screening Of Aqueous Media Using GC×GC-TOF-MS

      Aerosol Chemistry Systems Toxicology

      Characterization of Aerosol Exposure, Metabolism and Pharmacokinetics for Toxicological Assessment Using In Vitro Organotypical Airway Models

      Aerosol Chemistry Systems Toxicology

      In Vitro Test Systems for Aerosols Toxicology Assessment - Characterization of Exposure, Metabolism and Kinetics

      Aerosol Chemistry Systems Toxicology

      Applicability of Different Soft Nucleophiles for the Screening of Reactive Metabolites upon Microsomal Activation of Furan Mixtures and Cigarette Smoke

      Aerosol Chemistry Systems Toxicology

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.